bioRxivPharmacology & ToxicologyPreprint
Establishing an in vitro pipeline for the high-throughput quantification of epithelial permeability of gut bacterial metabolites
Amber Brauer-NikonowiD, Carlos Geert Pieter VoogdtiD, Nathan Vinícius RibeiroiD, Michael ZimmermanniD
Abstract
The epithelium of the human gastrointestinal tract is key for controlling the absorption of small molecules and for forming a tight barrier between the gut microbiota and the host, thereby maintaining metabolic homeostasis. Both the microbiota and the barrier function of the intestinal epithelium have a role in pharmacokinetic variability of medical drugs. In this study, we developed a high-throughput workflow to assess the absorption of bacterially produced (drug) metabolites by intestinal epithelial cells through the combination of anaerobic bacterial cultures and human-intestine derived Caco2 cell cultures in a transwell system. To functionally monitor the barrier integrity during the experiments, we introduced a panel of marker compounds, whose concentration kinetics on either side of the epithelial monolayer indicates barrier integrity and transport. We employed this workflow to systematically probe the effect of different gut bacterial species on the epithelial absorption of 482 drugs and their 172 bacterially produced metabolites. While we could recapitulate known bacterial drug biotransformation reactions and expected drug metabolite absorption profiles, we also identified 33 new bacteria-drug pairs for which bacterial biotransformation alters epithelial permeability. Further, we combined the developed experimental workflow with untargeted metabolomics analysis to systematically study epithelial permeability of metabolites naturally produced by gut bacteria. Tracking the absorption kinetics of 397 bacterially produced metabolites revealed that the majority (>79%) of these metabolites do not pass the Caco2 monolayer, illustrating its role as a physical and metabolic barrier. In summary, we present a highly adaptable high-throughput workflow to quantitatively study the metabolic interactions at the intestinal microbiota-host interface which can impact pharmacokinetics, toxicokinetics, and human physiology.
- organism: human
- assay: metabolomics
- research focus: drug response / drug discovery
- approach: experimental assay
- Citations
- 2
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Influence of Gut Microbiota on Oral Drug Absorption and Metabolism
Douglas A. Nelson, Vaishnavi Veerareddy, … Karunya K. Kandimalla·bioRxiv·Feb 16, 2025
- Gut bacteria generate prodrugs in situ increasing systemic drug exposure
Ting-Hao Kuo, Anoop Singh, … Michael Zimmermann·bioRxiv·Dec 9, 2025
- Systematic mapping of drug metabolism by the human gut microbiome
P. Chankhamjon, B. Javdan, … M. S. Donia·bioRxiv·Feb 3, 2019
- Human gut Actinobacteria boost drug absorption by secreting P-glycoprotein ATPase inhibitors
T. S. Kyaw, M. Sandy, … P. J. Turnbaugh·bioRxiv·Oct 13, 2022
- Ex vivo intestinal permeability assay (X-IPA) for tracking barrier function dynamics
H. Bootz-Maoz, A. Simon, … N. Yissachar·bioRxiv·Nov 8, 2022
- Microbiome-derived metabolite effects on intestinal barrier integrity and immune cell response to infection
L. Adams, X. Li, … D. M. Wall·bioRxiv·Feb 6, 2024